Navigation Links
Mylan Declares Quarterly Preferred Stock Dividend
Date:7/31/2008

PITTSBURGH, July 31 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on August 15, 2008, to holders of preferred stock of record as of August 1, 2008.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest-and highest quality-product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
2. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
3. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
4. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
5. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
6. Mylan Wins Generic Prilosec(R) Patent Litigation
7. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
8. Mylan Announces Final FDA Approval for Zaleplon Capsules
9. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
10. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... Beach, California (PRWEB) , ... July 24, 2017 ... ... commercialization of autologous fat (adipose) transfer systems announces the issuance of United States ... ‘324 patent) for its adipose filtration technology. The '398 and '324 patents ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the ... Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about ... in China. , The article by Zidor Aldama described the situation in which Chinese ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released a ... and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. ... she has risen above. , In “Memories,” readers get a firsthand look at what ...
(Date:7/24/2017)... Huntingdon Valley, PA (PRWEB) , ... July 24, 2017 , ... ... wind and rain storms wreak havoc across communities and often result in massive tree ... Top 3 actions homeowners can take now including tree trimming, tree cabling and hazardous ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology: